United Therapeutics Corporation (UTHR)

258,13 +2,99 (+1,17%) Alla chiusura: 04:00PM EDT

United Therapeutics Corporation

1000 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
https://www.unither.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 1.168

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.	Founder, Chairman & CEO	5,32M	56,15M	1955
Mr. Michael I. Benkowitz	President & COO	2,83M	7,83M	1972
Mr. James C. Edgemond	CFO & Treasurer	2,01M	1,49M	1968
Mr. Paul A. Mahon J.D.	Executive VP, General Counsel & Corporate Secretary	2,31M	13,2M	1964
Mr. Dewey Steadman C.F.A.	Head of Investor Relations	N/D	N/D	N/D
Ms. Holly Hobson	Associate Vice President of Human Resources	N/D	N/D	N/D
Kevin T. Gray	Senior Vice President of Strategic Operations & Logistics	N/D	N/D	N/D
Mr. Patrick Poisson	Executive VP of Technical Operations	N/D	N/D	1968
Dr. Leigh Peterson	Executive Vice President of Product Development & Xenotransplantation	N/D	N/D	N/D
Mr. Gil Golden	Senior VP & Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Governance aziendale

L'ISS Governance QualityScore di United Therapeutics Corporation al 29 aprile 2024 è 2. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 5; diritti degli azionisti: 3; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.